MedTrace Logo

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

NCT00430781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2015-05-08

Study results available
· View outcomes & findings →

Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer

Conditions

  • Neoplasms, Uterine Cervix
  • Metastatic Cervical Cancer

Interventions

DRUG

pazopanib (GW786034)

DRUG

lapatinib (GW572016)

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-07-31
Completion
2011-07-31

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • Estonia
  • France
  • Germany
  • India
  • Ireland
  • Italy
  • Mexico
  • Spain
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430781 on ClinicalTrials.gov